Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;11(3):297-300.
doi: 10.6004/jadpro.2020.11.3.16. Epub 2020 Apr 1.

Current and Future Directions for PARP Inhibition

Megan Grudem  1 , Andrea Wahner Hendrickson  1
Affiliations

Current and Future Directions for PARP Inhibition

Megan Grudem et al. J Adv Pract Oncol. 2020 Apr.

Abstract

Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other key factors.

PubMed Disclaimer

Conflict of interest statement

Ms. Grudem and Dr. Wahner Hendrickson have no conflicts of interest to disclose.

References

    1. Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J.,…Kindler, H. L. (2019). Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine, 381(4), 317–327. 10.1056/NEJMoa1903387 - DOI - PMC - PubMed
    1. Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Goncalves, A., Lee, K. H.,…Blum, J. L. (2018). Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine, 379(8), 753–763. 10.1056/NEJMoa1802905 - DOI - PMC - PubMed
    1. Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A.,…Matulonis, U. A. (2016). Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine, 375(22), 2154–2164. 10.1056/NEJMoa1611310 - DOI - PubMed
    1. Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M.,,…DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495–2505. 10.1056/NEJMoa1810858 - DOI - PubMed
    1. Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N.,…Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523–533. 10.1056/NEJMoa1706450 - DOI - PubMed

LinkOut - more resources